26-year old male dies from myocarditis less than 2 weeks after his first doze

A New Zealand man has died on November 17, 2021, after the Pfizer Covid-19 vaccine 'probably' caused a rare heart problem, authorities have revealed. This happened less than two weeks after taking his first dose on November 5. 

A preliminary postmortem examination identified myocarditis, a rare inflammation of the heart muscle, as the likely cause of death and New Zealand's Covid-19 Vaccine Independent Safety Monitoring Board said the issue was 'probably' brought on by the jab.

He started feeling 'flutters' a few hours after having his first dose of the vaccine but dismissed the symptoms as stress-related because he was in the process of selling and buying a house as well as planning a wedding.

Around 3am on November 17, the couple decided to go to hospital for 'reassurance' but he collapsed while getting ready to go in the bathroom and was later pronounced dead.   

The death is only New Zealand's second linked to a known but rare side effect from the vaccine after health authorities in August reported a woman had died after taking her doses. 


REFERENCES

Third death considered linked to COVID-19 vaccine | Ministry of Health NZ

New Zealand man, 26, died after Pfizer Covid vaccine 'probably' caused rare heart problem | Daily Mail Online

Dunedin man's death linked to vaccine | Otago Daily Times Online News (odt.co.nz)

'His death was so needless': Rory Nairn not warned of vaccine's myocarditis risk, inquest hears - NZ Herald

Pfizer: NZ coroner investigates Rory Nairn’s death after Covid-19 vaccine | Herald Sun

Coroner Confirms Pfizer Vaccine Caused New Zealand Man’s Death • Children's Health Defense (childrenshealthdefense.org)

Rory Nairn inquest: 'Death has not been forgotten' - NZ Herald

Coroner confirms Rory Nairn's death was due to Covid-19 vaccine | Stuff.co.nz


Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more